Register to view the archived recording here.
Tacere Considers Sale of Company as Pfizer Exercises Option to HCV Program
While Tacere is weighing the possible expansion of its pipeline, having met this milestone in its flagship drug-development program, the company's management has set its sights on exiting the field through the sale of the company to a bigger player.
New to GenomeWeb? Register here quickly.